Boardroom Alpha
Meeting calendar
PRCT · Annual meeting · Tuesday, June 9, 2026

Procept Biorobotics Corp

3 nominees · 3 ballot items.

Elect three Class II directors (Antal Desai, Mary Garrett, Frederic Moll, M.D.); ratify PwC as the independent registered public accounting firm for 2026; and approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers (say-on-pay).

Market cap
$1.1B
1Y TSR
-63.1%
Board grade
C-
Record date
Apr 10, 2026
Filing
DEF 14A
Meeting concluded · Jun 9, 2026

Follow how the vote landed and what changed on Procept Biorobotics Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect the three nominees for Class II directors (Antal Desai, Mary Garrett, Frederic Moll, M.D.) to serve until the 2029 annual meeting and until their successors are duly elected and qualified.

  2. 2

    Ratification of the Selection of the Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  3. 3

    Approval, on a Non-Binding Advisory Basis, of the Compensation of Our Named Executive Officers (Say-on-Pay

    ManagementBoard: FOR

    Non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement (the Compensation Discussion and Analysis, compensation tables and accompanying narrative).

    More detail

    This proposal asks shareholders to cast a non-binding advisory vote approving the Company’s named executive officer compensation as disclosed in the proxy statement. Management seeks this approval to confirm alignment between executive pay practices and stockholder interests and to validate the Compensation Committee’s pay-for-performance design, which emphasizes variable compensation and long-term equity awards. The context includes a CEO transition in 2025 with a significant new-hire package for the incoming CEO (including sign-on cash, buy-out RSUs and option awards) and continuation of incentive structures (annual bonus tied to corporate and individual metrics, PSUs tied to revenue and adjusted EBITDA, and time-vested RSUs and options). The Compensation Committee approved discretionary adjustments in 2026 to the annual bonus payout after considering revenue shortfalls, other operational achievements, and strategic shifts under new leadership; the Committee also retained robust governance safeguards such as independent consultant advice, clawback policy, stock ownership guidelines, and no tax gross-ups. Management argues that the overall program is market-competitive, aligned with long-term stockholder value, and supported by prior stockholder outreach and a strong 2025 say-on-pay approval (>95%). Critics could point to the size of certain one-time new-hire awards and transition-related payments and the discretionary upward adjustment to bonus payouts despite some metrics falling short, raising questions about strictness of pay-for-performance discipline. The Board counters that the transition-related awards were necessary to recruit an experienced CEO and to retain continuity, and that discretion was applied to account for strategic changes and other metrics beyond simple revenue attainment. The advisory nature of the vote means it will not bind the Board, but the Board has committed to consider the vote’s outcome in future compensation decisions, balancing retention, recruitment, and alignment with stockholder value creation. Overall, the proposal is a conventional say-on-pay request but set against the specific company context of leadership change and targeted performance measures, requiring stockholders to weigh long-term retention and succession needs against strict metric-based pay outcomes.

Director elections

Nominees on the ballot3

Independent
Tenure on this board
4.5 yrs
Also a director at
Omnicell Inc (OMCL)
Independent
Tenure on this board
4.8 yrs
Also a director at
Ss Innovations International Inc (SSII)
Ownership

Top institutional holders10

Latest 13F quarter
1T. Rowe Price Investment Management, Inc.5.8%3,273,794$82M
2VANGUARD PORTFOLIO MANAGEMENT LLC4.3%2,421,362$61M
3VANGUARD CAPITAL MANAGEMENT LLC4.2%2,399,067$60M
4Chicago Capital, LLC3.8%2,160,587$54M
5BlackRock, Inc.3.8%2,157,456$54M
6Prosight Management, LP3.4%1,945,000$49M
7MACKENZIE FINANCIAL CORP3.0%1,720,738$43M
8BlackRock, Inc.2.9%1,631,433$41M
9BNP Paribas Asset Management Holding S.A.2.7%1,557,677$39M
10BNP Paribas Asset Management Holding S.A.2.7%1,530,597$38M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Procept Biorobotics Corp 2026 annual meeting?
Procept Biorobotics Corp (PRCT) holds its 2026 annual shareholder meeting on Tuesday, June 9, 2026.
What is the record date for the Procept Biorobotics Corp 2026 meeting?
The record date for the Procept Biorobotics Corp 2026 meeting is Friday, April 10, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Procept Biorobotics Corp's 2026 meeting?
The board is presenting 3 director nominees at the Procept Biorobotics Corp 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Procept Biorobotics Corp 2026 meeting?
Shareholders will vote on 3 proposals at the Procept Biorobotics Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer